https://www.selleckchem.com/products/4u8c.html
2% (90/166), p 0.016; model 2 35.3% (41/116) versus 56.9% (66/116), p 0.001). On multivariate analysis, nebulized colistin was an independent factor associated with fewer day 14 clinical failures (model 1 adjusted odds ratio (aOR) 0.59, 95% CI 0.37-0.92; model 2 aOR 0.37, 95% CI 0.21-0.65). Nebulized colistin was not associated independently with a lower 14-day mortality rate in the time-dependent analysis in both models 1 and 2. Adjunctive nebulized colistin was associated with lower day 14 clinical failure rate, but not lower 14-day mort
Like
Comment
Share
